957065-99-5

Basic information

• Product Name: Methyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)picolinate
• Synonyms: 2-(Methylcarboxy)pyridine-6-boronic acid pinacol ester;2-Methoxycarbonyl-5-pyridineboronic acid;methyl 5-(tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-2-carboxylate;methyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-2-carboxylate;2-Methoxycarbonyl-5-pyridineboronic acid, pinacol ester;Methyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)picolinate;6-Methoxycarbonylpyridine-3-boronic acid pinacol ester;2-(Methylcarboxy)pyridine...
• CAS NO: 957065-99-5
• Molecular Formula: C₁₃H₁₈BNO₄
• Molecular Weight: 263.1
• Product Categories: blocks;BoronicAcids;Carboxes;Pyridines;Ester;Organoborons;Pyridine
• Mol File: 957065-99-5.mol

Chemical Properties

• Boiling Point: 383.9 °C at 760 mmHg
• Flash Point: 186 °C
• Appearance: /
• Density: 1.12
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 1.68±0.12(Predicted)
• CAS DataBase Reference: Methyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)picolinate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)picolinate(957065-99-5)
• EPA Substance Registry System: Methyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)picolinate(957065-99-5)

Safety Data

• Hazardous Substances Data: 957065-99-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)picolinate is used as a key reagent for the synthesis of complex organic molecules in the pharmaceutical industry. Its role in Suzuki-Miyaura cross-coupling reactions enables the formation of carbon-carbon bonds, which are crucial for the development of new and effective drugs.
Used in Agrochemical Industry:
In the agrochemical industry, Methyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)picolinate is employed as a reagent for the synthesis of complex organic molecules that serve as active ingredients in various agrochemical products. Its ability to facilitate the formation of biaryl compounds through Suzuki-Miyaura cross-coupling reactions is vital for the creation of innovative and efficient agrochemicals.
Used in Fine Chemicals Industry:
Methyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)picolinate is used as a building block in the synthesis of complex organic molecules in the fine chemicals industry. Its versatility and importance in the formation of carbon-carbon bonds through Suzuki-Miyaura cross-coupling reactions make it a valuable component in the production of high-quality fine chemicals.
Used in Organic Synthesis Research:
Methyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)picolinate is utilized as a research tool in organic synthesis, where its unique properties and reactivity are explored to develop new synthetic methods and pathways. Its role in Suzuki-Miyaura cross-coupling reactions provides insights into the selective and efficient formation of biaryl compounds, contributing to the advancement of organic chemistry.

Upstream product

• 624-28-2 2,5-dibromopyridine 
• 29682-15-3 methyl 5-bromopicolinate 
• 73183-34-3 bis(pinacol)diborane 

Downstream Products

• 1254171-44-2 5-(2-(2-chloro-6-fluorophenyl)-4-cyano-1H-imidazol-5-yl)picolinic acid 
• 60611-59-8 5-Benzyl-2-pyridincarbonsaeure 
• 60611-82-7 methyl 5-benzylpicolinate 
• 1621254-08-7 methyl 5-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)picolinate 
• 1464153-93-2 methyl 5-(3-(4-cyanophenyl)imidazo[1,2-a]pyrazin-6-yl)picolinate 
• 1415130-24-3 ethyl 3-(5-(2-(((3',4'-dichloro-2-fluoro-[1,1'-biphenyl]-4-yl)amino)methyl)-5-fluorophenyl)picolinamido)propanoate 
• 1415130-22-1 ethyl 3-(5-(2-(((4-bromo-3-fluorophenyl)amino)methyl)-5-fluorophenyl)picolinamido)propanoate 

Relevant articles and documents

Fusaric acid and derivatives as novel antimicrobial agents

The synthesis and screening of several fusaric acid (FA) and analogues against five common clinical pathogens (gram-positive and gram-negative) and in vitro hemolytic activity assay in human red blood cells, for the first time, were reported. The biological results reveal that FA and its analogues exhibited moderate antimicrobial activities. Compounds 2–5 and 7 showed growth inhibitory activity in gram-positive bacteria. Compounds 6 and 9 showed growth inhibitory activity in both gram-positive and gram-negative bacteria. None of the compounds induce hemolysis, which is potent for future drug development on this template. In addition, the structure–activity relationship and docking studies are discussed.

Small molecule compound

The invention provides a small molecular compound, The small molecular compound is characterized by having a structure as shown in the following molecular general formula, wherein X1 and X2 are selected from carbon or nitrogen, G1 is a carbon ring or a heterocyclic ring with aromaticity, any one or more hydrogen atoms on the G1 ring are substituted by R1, wherein R1 is selected from nitrogen-containing groups. The small molecule compound can be used as an efficient and specific JAK kinase inhibitor, especially a Tyk2 inhibitor, and/or a JAK1 inhibitor, and/or a JAK1/Tyk2 dual inhibitor, or a Tyk2/JAK1 dual inhibitor or a Tyk2/Jak2 dual inhibitor.

Fusaric acid and analogues as Gram-negative bacterial quorum sensing inhibitors

Taking advantage of microwave-assisted synthesis, efficient and expedite procedures for preparation of a library of fusaric acid and 39 analogues are reported. The fusaric acid analogues were tested in cell-based screening assays for inhibition of the las and rhl quorum sensing system in Pseudomonas aeruginosa and the lux quorum sensing system in Vibrio fischeri. Eight of the 40 compounds in the library including fusaric acid inhibited lux quorum sensing and one compound inhibited activity of the las quorum sensing system. To our delight, none of the compounds showed growth inhibitory effects in the tested concentration ranges.

BENZOTHIAZOLES AND AZA-ANALOGUES THEREOF USE AS ANTIBACTERIAL AGENTS

The present invention provides Gyrase B and/or Topoisomerase IV par E inhibitors, which can be used as antibacterial agents. Compounds disclosed herein can be used for treating or preventing conditions caused by or contributed by gram positive, gram negative and anaerobic bacteria, more particularly against, for example, Staphylococci, Streptococci, Enterococci, Haemophilus, Pseudomonas spp., Acenetobacter spp., Moraxalla spp., Chlamydia spp., Mycoplasma spp., Legionella spp., Ktycobacterium spp., Helicobacter, Clostridium spp., Bacteroides spp., Coryne bacterium, Bacillus spp., Enterobactericeae,' (E.coli, Klebsiella spp., Proteus spp.,etc. ) or any combination thereof Also provided, are processes for preparing compounds disclosed herein, pharmaceutical compositions containing compounds disclosed herein, and methods of treating bacterial infections. (Formula)